HER2-Negative Breast Cancer: Subtypes and Treatment

HER2-negative breast cancer accounts for roughly 80 to 85 percent of all breast cancer diagnoses, making it far more common than the HER2-positive form that often dominates headlines. The label simply means a tumor does not overexpress the HER2 protein, which normally sits on cell surfaces and promotes growth. But “HER2-negative” is not a single disease. It spans a wide spectrum, from slow-growing, hormone-driven tumors that respond well to pills blocking estrogen, to aggressive triple-negative cancers that until recently had few targeted options. Understanding where your tumor falls on that spectrum changes nearly everything about how it is treated, how it behaves, and what newer therapies you may qualify for.

What HER2-Negative Actually Means

Pathologists test every breast cancer biopsy for three things: estrogen receptors (ER), progesterone receptors (PR), and HER2 protein levels. HER2 is scored by immunohistochemistry on a scale from 0 to 3+. A score of 3+ (or a 2+ confirmed by a second test called FISH) means the cancer is HER2-positive. Everything else falls under the HER2-negative umbrella. That umbrella covers two fundamentally different groups. The larger group, roughly two-thirds of all breast cancers, is hormone receptor-positive and HER2-negative (HR+/HER2−). These tumors grow in response to estrogen and tend to be less aggressive. The smaller group is triple-negative breast cancer (TNBC), which lacks estrogen receptors, progesterone receptors, and HER2, and behaves quite differently.

Within hormone receptor-positive disease alone, pathologists further distinguish luminal A-like tumors, which grow slowly and have low proliferation, from luminal B-like tumors, which are more aggressive despite still being hormone-driven. Both are HER2-negative, but a luminal A tumor in a postmenopausal woman carries a very different prognosis than a luminal B tumor in a younger patient. The point is that calling a cancer “HER2-negative” tells you what the tumor lacks, not what drives it. The driver is what determines treatment.

Treatment of Hormone Receptor-Positive, HER2-Negative Disease

For the majority of HER2-negative breast cancers, those that are hormone receptor-positive, the backbone of treatment is endocrine therapy. This means drugs that block or lower estrogen: tamoxifen, aromatase inhibitors like letrozole or anastrozole, or the estrogen receptor degrader fulvestrant. The rationale is straightforward. These tumors rely on estrogen receptor signaling as the main engine of their growth, and shutting that engine down is an effective strategy for many patients.¹ In early-stage disease, five or ten years of endocrine therapy after surgery substantially reduces recurrence risk.

Over the past decade, the treatment of advanced HR+/HER2− breast cancer was transformed by CDK4/6 inhibitors, drugs like palbociclib, ribociclib, and abemaciclib. These block proteins that push cancer cells through their growth cycle. In a pooled analysis by the FDA across seven trials, adding a CDK4/6 inhibitor to endocrine therapy extended the time before disease worsened by a median of nearly nine months compared to endocrine therapy alone, with consistent benefits across patient subgroups.² Among patients receiving a first-line aromatase inhibitor, the combination pushed median progression-free survival to about 28 months, versus roughly 15 months with endocrine therapy alone. A separate meta-analysis confirmed a meaningful improvement in overall survival as well.³

CDK4/6 inhibitors are not without side effects. Fatigue is the most commonly reported symptom, affecting about a third of patients in one large cross-sectional survey. Hair thinning and weakness also come up, though the severity varies by specific drug.⁴ Blood count changes, particularly drops in white blood cells (neutropenia), are common across all CDK4/6 inhibitors and require regular monitoring.⁵ Despite these issues, the combination has become standard-of-care for most patients with advanced HR+/HER2− breast cancer because the survival gains outweigh the manageable side effects for the majority.

Triple-Negative Breast Cancer Within the HER2-Negative Category

Triple-negative breast cancer, which lacks all three standard receptors, makes up about 10 to 15 percent of breast cancers. It tends to grow faster, strikes younger women more often, and historically had fewer targeted options because there was no obvious receptor to block. For years, chemotherapy was the primary tool. In neoadjuvant settings (chemotherapy given before surgery), TNBC responds to chemotherapy more dramatically than HR+ disease. In one large trial, nearly 28 percent of patients with triple-negative tumors achieved a pathological complete response with standard chemotherapy, compared to about 8 percent of hormone receptor-positive patients.⁶ Paradoxically, the same aggressiveness that makes TNBC dangerous also makes it more chemosensitive.

The immune landscape helps explain some of this. TNBC tumors tend to harbor more immune cells within and around them than HR+/HER2− tumors do. Spatial analyses have found that TNBC has a higher proportion of certain immune cells, particularly CD8-positive cells (the immune cells that directly kill cancer cells), compared to hormone receptor-positive HER2-negative tumors.⁷ This richer immune infiltrate is one reason why immunotherapy has gained traction in TNBC but has not yet worked as well in HR+ disease.

Immunotherapy for Triple-Negative HER2-Negative Breast Cancer

Pembrolizumab, an immune checkpoint inhibitor, has changed the treatment landscape for TNBC. In the KEYNOTE-522 trial, adding pembrolizumab to chemotherapy before surgery raised the rate of pathological complete response from about 51 percent with chemotherapy alone to roughly 65 percent. The combination also reduced early events of recurrence or disease progression.⁸ For early-stage TNBC, this combination is now standard.

In advanced or metastatic TNBC, the picture is more nuanced. The benefit of adding pembrolizumab to chemotherapy depends heavily on how much PD-L1 protein the tumor expresses. Among patients whose tumors had a combined positive score (CPS) of 10 or higher, median overall survival was about 23 months with pembrolizumab-chemotherapy versus about 16 months with chemotherapy alone. But when researchers included patients with lower PD-L1 expression, the survival difference shrank and was not statistically significant.⁹ PD-L1 testing before starting immunotherapy for metastatic TNBC has therefore become essential for selecting the patients most likely to benefit.

The HER2-Low Revolution

One of the biggest shifts in breast oncology has been the realization that “HER2-negative” is not all the same at the molecular level. A tumor scored as IHC 1+ or IHC 2+ (without FISH amplification) expresses some HER2 protein, just not enough to qualify as HER2-positive. This intermediate zone is now called HER2-low, and it turns out roughly half of all traditionally “HER2-negative” cancers fall into it. For decades, the distinction between IHC 0 and IHC 1+ did not matter clinically. Now it does.

The drug that forced this reclassification is trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that delivers a potent chemotherapy payload directly to cells expressing even small amounts of HER2. In the landmark DESTINY-Breast04 trial, T-DXd roughly doubled progression-free survival in patients with HER2-low metastatic breast cancer compared to standard chemotherapy, with a median of about 10 months versus 5 months across all patients. Overall survival was also significantly longer, at about 23 months versus 17 months.¹⁰ These results held in both the hormone receptor-positive cohort and the smaller triple-negative cohort.

Even more provocatively, the phase 2 DAISY trial found that T-DXd produced responses in about 30 percent of patients whose tumors were scored IHC 0, the very lowest level of HER2 expression.¹¹ This suggests the drug may work through mechanisms beyond just targeting HER2-expressing cells, possibly through a bystander effect where the released chemotherapy kills neighboring cancer cells. It also raises the question of whether the current scoring system is precise enough to determine who benefits.

The Diagnostic Challenge of Scoring HER2-Low

Reliably distinguishing IHC 0 from IHC 1+ is harder than it sounds. Earlier scoring guidelines were designed to separate positive from negative, not to draw a fine line between zero and low expression. Studies have found considerable disagreement among pathologists at exactly this boundary. One study reported a discordance rate of about 41 percent in distinguishing HER2 0 from HER2 1+/2+/3+, while the discordance between 3+ and non-3+ was only about 11 percent.¹² Among pathologists specifically trained in HER2-low scoring, agreement improves substantially, with one study finding overall agreement above 85 percent across all scores and above 90 percent for the HER2-low cutoff.¹³ However, without targeted training, some pathologist pairs showed virtually no agreement on HER2-low cases, with faint staining, cytoplasmic blush, and tissue artifacts being the main sources of confusion.¹⁴

This matters because being classified as IHC 0 versus IHC 1+ can now determine whether you are eligible for T-DXd.¹⁵ If your tumor was tested years ago, before the HER2-low distinction had clinical significance, it may be worth discussing with your oncologist whether retesting could change your treatment options.

Genomic Tests That Guide Chemotherapy Decisions

For patients with early-stage HR+/HER2− breast cancer, one of the most anxiety-provoking questions is whether you need chemotherapy on top of endocrine therapy. Genomic assays like Oncotype DX help answer that. The test analyzes the expression of 21 genes in the tumor and produces a recurrence score. In real-world practice, the adoption of Oncotype DX has led to meaningful reductions in chemotherapy use. One study found that chemotherapy recommendations dropped from about 31 percent before the test was available to about 18 percent after, with the sharpest reductions among patients whose scores indicated low risk of recurrence.¹⁶ A large Brazilian cohort confirmed broad utility, with the test associated with roughly a 13 percentage point absolute reduction in chemotherapy recommendations overall, and an even larger reduction in certain subgroups like postmenopausal women with limited lymph node involvement.¹⁷

The practical takeaway is that many patients with HR+/HER2− early breast cancer can safely skip chemotherapy and its side effects if their genomic risk score is low. This represents a significant quality-of-life benefit, and if your oncologist has not discussed genomic testing, it is worth asking about it.

PARP Inhibitors for BRCA-Mutated Tumors

About 5 to 10 percent of breast cancers arise in people carrying inherited mutations in the BRCA1 or BRCA2 genes. These mutations are more common in triple-negative disease but can appear in any subtype. Tumors with BRCA mutations have a defect in one of their DNA repair pathways, and PARP inhibitors exploit that weakness. The drugs block a backup DNA repair mechanism, leaving BRCA-mutant cancer cells unable to fix critical damage while sparing normal cells that still have working BRCA.¹⁸ Two PARP inhibitors, olaparib and talazoparib, have shown improved outcomes over standard chemotherapy in metastatic BRCA-mutated, HER2-negative breast cancer.

Research is also expanding the concept beyond inherited BRCA mutations. Some tumors have somatic (non-inherited) mutations or other defects in the same DNA repair pathway, and these may also respond to PARP inhibitors.¹⁹ This broader group is sometimes called “BRCAness” or homologous recombination deficiency. Identifying these patients reliably remains an active area of investigation, but it means the population that may benefit from PARP inhibitors could be larger than just those with known inherited mutations.

When Endocrine Therapy Stops Working

Resistance to endocrine therapy is one of the central challenges in HR+/HER2− breast cancer. While many patients do well on hormonal treatment for years, the cancer eventually finds workarounds. Two of the best-understood escape routes involve mutations in the estrogen receptor gene itself (ESR1) and overactivation of the PI3K/Akt/mTOR signaling pathway.

ESR1 mutations appear in up to about 20 percent of patients with metastatic ER-positive disease who have been treated with aromatase inhibitors.²⁰ These mutations cluster in the part of the estrogen receptor that normally binds estrogen, allowing the receptor to switch on without any estrogen present. That makes aromatase inhibitors, which work by lowering estrogen levels, largely useless against these mutant cells. The mutations can also reduce the effectiveness of tamoxifen and fulvestrant, though to a lesser degree.²¹ Newer drugs, including oral selective estrogen receptor degraders (oral SERDs), are being developed specifically to overcome this problem. Liquid biopsies that detect ESR1 mutations in circulating tumor DNA can identify this resistance mechanism early, potentially allowing a treatment switch before overt disease progression.

The PI3K/Akt/mTOR pathway is another frequent accomplice. When this signaling cascade becomes overactive, it can bypass estrogen receptor dependence and keep cancer cells growing despite hormonal blockade. Drugs targeting this pathway are already approved for patients who relapse on first-line endocrine therapy. Alpelisib, a PI3K inhibitor, has shown benefit specifically in tumors harboring PIK3CA mutations, and everolimus, an mTOR inhibitor, demonstrated progression-free survival gains in the BOLERO-2 trial.²² Identifying which resistance pathway is active in a given patient increasingly guides the choice of second- or third-line therapy.

Antibody-Drug Conjugates Beyond T-DXd

Trastuzumab deruxtecan is not the only antibody-drug conjugate making headway in HER2-negative breast cancer. Sacituzumab govitecan targets a different protein, Trop-2, which is widely expressed on many breast cancers regardless of HER2 status. It is now approved for previously treated triple-negative and HR+/HER2− metastatic breast cancer based on improvements in both progression-free and overall survival compared to standard chemotherapy.²³ A meta-analysis across multiple tumor types found that the most notable side effect was grade 3 or 4 neutropenia, occurring in roughly 37 percent of patients, while other severe side effects were each below 10 percent.²⁴

Having two different antibody-drug conjugates that work in HER2-negative disease through different targets is a meaningful development. It means that even if a tumor has zero HER2 expression and cannot be treated with T-DXd under current guidelines, sacituzumab govitecan targeting Trop-2 may still be an option. Research is now exploring whether combining these agents with immunotherapy can further improve outcomes.

How HER2-Negative Subtypes Spread Differently

The subtype of a HER2-negative breast cancer influences not just treatment options but where the cancer is most likely to spread. Hormone receptor-positive tumors have a well-documented preference for bone, often appearing there as a first metastatic site. The second most common sites for HR-positive tumors tend to be the lung and liver.²⁵ HR-positive bone metastases are often more manageable with current therapies and can sometimes be controlled for years.

Triple-negative cancers, by contrast, tend to spread to visceral organs like the lung more readily, with one analysis finding about a fourfold higher odds of lung involvement compared to other subtypes.²⁶ Brain metastasis is also more of a concern with TNBC and HER2-positive disease than with HR-positive, HER2-negative cancers. These differing patterns matter for surveillance. If you have HR+/HER2− disease, your oncologist may be more attentive to bone scans, while triple-negative follow-up more often includes imaging of the chest and brain.

Tumor-Infiltrating Lymphocytes as a Prognostic Clue

The density of immune cells found within and around a tumor, called tumor-infiltrating lymphocytes (TILs), has emerged as a useful prognostic marker across HER2-negative breast cancer. A meta-analysis found that patients with high levels of stromal TILs who received neoadjuvant chemotherapy were significantly more likely to achieve a complete pathological response. The effect held across subtypes, but was particularly strong in HR-positive disease, where high TILs were associated with more than triple the likelihood of a complete response compared to low TILs.²⁷ In triple-negative disease, the effect was also significant but somewhat smaller in magnitude, likely because TNBC already tends to have more immune infiltration at baseline. TIL assessment is not yet a routine clinical decision-maker in the way that Oncotype DX is, but it is increasingly being incorporated into research protocols and may eventually help fine-tune treatment intensity.

Male Breast Cancer in the HER2-Negative Landscape

Breast cancer in men is rare, accounting for less than 1 percent of all breast cancer cases, but it is overwhelmingly HER2-negative. An international characterization of male breast cancer found that about 99 percent of tumors were estrogen receptor-positive, and roughly 97 percent were HER2-negative. The most common molecular profiles were luminal B-like/HER2-negative and luminal A-like, making up about 49 percent and 42 percent of cases, respectively. Triple-negative male breast cancer was vanishingly rare, seen in only about 0.3 percent of cases.²⁸ Treatment for male breast cancer largely follows the same principles as for HR+/HER2− female breast cancer, centered on endocrine therapy, though men are typically given tamoxifen rather than aromatase inhibitors as a starting point. The evidence base is thinner because men are rarely included in the large trials that shape treatment guidelines, so much of the management is extrapolated from female data.

Predicting Chemotherapy Response in HER2-Negative Tumors

Researchers are working to move beyond one-size-fits-all approaches by predicting which HER2-negative patients will respond well to neoadjuvant chemotherapy before surgery. A recent study developed a model using routine pathology markers to estimate the probability of achieving a pathological complete response in HER2-negative patients. In their dataset, about 23 percent of patients achieved that goal. The model performed well enough to stratify patients into groups where the prognostic significance of a complete response varied dramatically: among patients the model predicted were most likely to respond, actually achieving a complete response carried a much stronger survival benefit than it did among patients predicted to be unlikely responders.²⁹ Tools like this could eventually help clinicians identify which patients benefit most from aggressive pre-surgical chemotherapy and which might safely de-escalate treatment.

A separate question being explored involves patients with ER-low tumors, a gray zone where estrogen receptors are technically present but at low levels (1 to 10 percent). These cancers behave more like TNBC in some ways. In a small real-world study, patients with ER-low/HER2-negative tumors treated with pembrolizumab plus chemotherapy achieved pathological complete response rates around 60 percent, closer to what is seen in TNBC than in typical HR-positive disease.³⁰ This raises the possibility that some patients currently classified as hormone receptor-positive may benefit more from immunotherapy-based regimens than from endocrine-focused approaches.